Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.53 |
| ▸ | MTOR | P42345 | 11/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556110 | 1.00 | ALPL (0.55) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL29434933 | 1.00 | ALPL (0.55) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL22447700 | 0.91 | ALPL (0.52) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL30333601 | 0.90 | ALPL (0.54) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL807202 | 0.90 | ALPL (0.49) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL18759850 | 0.90 | ALPL (0.54) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL798076 | 0.90 | ALPL (0.47) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL15560224 | 0.90 | ALPL (0.58) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL29555742 | 0.90 | ALPL (0.58) | ALPLPIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL30333038 | 0.90 | ALPL (0.58) | ALPLPIK3CAMTORPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110963991-A | PI3K inhibitor and preparation method and application thereof | 嘉兴学院 | 2020-04-07 | — | — | CN | claimed |
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| EP-4169918-B1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3K FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4169917-B1 | QUINAZOLINE COMPOUNDS AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2024188229-A1 | SALT FORM AND CRYSTAL FORM OF QUINAZOLINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川汇宇制药股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| EP-3560921-B1 | QUINAZOLINE COMPOUND, PREPARATION METHOD, APPLICATION AS PI3K INHIBITOR FOR THE TREATMENT OF CANCER, AND PHARMACEUTICAL COMPOSTION THEREOF | INST MATERIA MEDICA CAMS (CN) | 2024-08-14 | — | — | EP | disclosed |
| EP-4406948-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024109233-A1 | PYRIMIDOAROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川汇宇制药股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| WO-2010125082-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125082-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | REN, ACE, AGTR2 | ALPL 937/4885PIK3CA 1232/4885MTOR 3521/4885 |
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3R5, JAK1 | ALPL 3258/4885PIK3CA 1/4885MTOR 15/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | ALPL 4135/4885PIK3CA 70/4885MTOR 517/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | ALPL 3399/4885PIK3CA 2/4885MTOR 34/4885 |
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3C2A, PIK3R5 | ALPL 2901/4885PIK3CA 1/4885MTOR 11/4885 |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | ALPL 3229/4885PIK3CA 8/4885MTOR 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.